A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer

Abstract

BACKGROUND: Salivary gland cancers are rare, histologically diverse, and varied in their biologic behavior and responsiveness to systemic therapy. To the authors' knowledge, there currently is no standard chemotherapy for these tumors, but cisplatin-based regimens are often used. This phase 2 trial evaluated the combination of gemcitabine with cisplatin (carboplatin in those with protocol-defined contraindications to cisplatin). METHODS: Fit, consenting adult patients had advanced, metastatic, or locoregionally recurrent salivary gland cancer (any histologic subtype) that was not suitable for radiation or surgery. Therapy was comprised of gemcitabine at a dose of 1000 mg/m 2 administered intravenously on Days 1 and 8, and cisplatin at a dose of 70 mg/m 2 on Day 2, of a 21-day cycle.

Re-irradiation of adenoid cystic carcinoma: Analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy

“…2s). However, compared to available chemotherapy data [45][46][47], objective treatment response (56.6%) and response duration (median local control: 19 months) using re-irradiation is still impressive, especially considering the moderate toxicity profile and treatment alternatives: with the most effective CAP regime including cisplatin already given, expected objective response rates of second or third line treatment will be less than 20% (Supplement Table 2s). Re-irradiation with carbon ions may therefore be a valuable tool in palliative treatment of ACC in order to avoid systemic treatment as long as possible and prevent local complications due to aggressive local tumour growth.…”

The status of platinum anticancer drugs in the clinic and in clinical trials

“…Once aquated carboplatin yields the same active component as cisplatin and forms the same DNA adducts, and is therefore only clinically useful for treating the same cancer types. Carboplatin is now the drug of choice for ovarian cancer, in preference to cisplatin, and has recently undergone additional Phase II and III trials for the treatment of salivary gland cancer 12 and advanced mullerian cancer 13 to further expand its clinical application.…”

Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy

“…The choice of therapy was based on several small phase ii studies identifying that combination as active in the treatment of malignant salivary gland tumours, although with efficacy varying by histologic subtype [10][11][12] . Newer combinations such as carboplatin-paclitaxel or cisplatin-gemcitabine have demonstrated moderate activity in small trials involving salivary gland tumours with a mix of histologies 13,14 . Because of the absence of her2 amplification, trastuzumab was not selected as therapy for our patient.…”